Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vietnam Pleads For Greater Drug MNC Investment In Local Industry

This article was originally published in PharmAsia News

Executive Summary

Vietnam's Ministry of Health is asking for help from multinational pharmaceutical companies to step up their investments in the country and support locally made products. Although Vietnam issued licenses in 2008 to 37 foreign direct-investment projects, only 25 were implemented and only a single additional investment license was granted for local drug production. The ministry noted the great potential of Vietnam's pharma sector, yet foreign investments in the industry still account for a relatively small amount of the FDI, down 25 percent from the previous year. Foreign drug makers appear interested only in seeking local suppliers for their products rather than investing in local manufacturing plants, the director of the ministry's drug administration said. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC070867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel